The course of COVID-19 in patients with psoriasis was characterized and factors associated with hospitalization were identified in an international case study.
RediTrex is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis.
A case report of a man with plaque psoriasis and comorbidities that include psoriatic arthritis and ulcerative colitis.
A novel study investigates an in-class IL-23 inhibitor switch from guselkumab to risankizumab for patients with psoriasis.
Early efforts to characterize the efficacy of treatment of psoriasis with ustekinumab in pediatric patients are reviewed.
VCAM-1 and E-selectin levels and their relationship with psoriasis severity were evaluated.
The 52-week double-blind, placebo-controlled ULTIMATE study included 166 adult biologic-naive patients with active psoriatic arthritis.
Clinical and positive psychological variables that contribute significantly to psoriasis disability were identified.
PASI score association with abnormal physiology as defined by low V/M independent of non-calcified coronary burden was investigated.
A phase 3 trial evaluating the efficacy and safety of deucravacitinib (BMS-986165; Bristol Myers Squibb), a novel, oral, selective TYK2 inhibitor, for the treatment of patients with moderate to severe plaque psoriasis met both co-primary and secondary end points.
